Search

A Warm Congratulations to Dr. Laurence Hurley

Updated: Mar 28

We congratulate Reglagene's Chief Scientific Officer Dr. Laurence Hurley for the granting of FDA Fast Track status for Pidnarulex, the only DNA quadruplex-targeting therapy that is active in human clinical trials. Pidnarulex is for ovarian and breast cancer patients presenting as BRCA1/2 or PALB2 positive. Dr. Hurley was the CSO at Cylene during the preclinical development of Pidnarulex. It is his second quadruplex therapy to reach clinical testing. Dr. Hurley won't stop his contributions to cancer treatments there and is actively working on developing a new brain cancer therapy with the Reglagene team!


https://www.cancernetwork.com/view/fda-grants-fast-track-designation-to-pidnarulex-in-brca1-2-palb2-ovarian-and-breast-cancer

Recent Posts

See All

It's great to see the Desert Angels featured in BizTucson Magazine. Desert Angels CEO Joann MacMaster discusses how they changed their operations during the pandemic to help new and existing portfolio

Thank you to Amanda Bruno and our friends at the City of Tucson for featuring Reglagene in the latest episode of #BizBitesTucson! Please click the link below to watch the video. https://www.youtube.co